

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB 3235-Number: 0104 Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)						
1. Name and Address of Reporting	2. Date of Event Requiring	g 3. Issuer Name and Ticker or Trading Symbol				
Person [*]	Statement	Cellectar Biosciences, Inc. [CLRB]			LRB]	
Loren Stefan	(Month/Day/Year) 06/15/2015					
(Last) (First) (Middle)	00/15/2015	4. Relationship of Reporting			5. If Amendment, Date Original	
C/O CELLECTAR		Person(s) to Issuer			Filed(Month/Day/Year)	
BIOSCIENCES, INC., 3301		(Check all applicable)				
AGRICULTURE DRIVE		XDirector10% Owner Officer (give Other (specify				
(Street)	1	title below) below)			6. Individual or Joint/Group	
MADISON, WI 53716					Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person	
(City) (State) (Zip)	Table I - Non-Derivative Securities Beneficially Owned					
1.Title of Security	2. Amount of	f Securities	3.	4. Natu	are of Indirect Beneficial	
(Instr. 4)	Beneficially	Owned	Ownership	Owner	rship	
	(Instr. 4)		Form: Direct	(Instr.	5)	
			(D) or			
			Indirect (I)			
			(Instr. 5)			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		Derivative Security		Price of	5. Ownership	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date		Amount or Number of Shares	Derivative Security: Security Direct (D) or Indirect (I) (Instr. 5)		
Employee Stock Option (right to buy)	<u>(1)</u>	06/15/2025	Common Stock	10,000	\$ 2.64	D	

Reporting Owners

Reporting Owner Name / Address	Relationships				
Reporting Owner Name / Address	Director 10% Owner O		Officer	Other	
Loren Stefan C/O CELLECTAR BIOSCIENCES, INC. 3301 AGRICULTURE DRIVE MADISON, WI 53716	Х				

Signatures

/s/ Chad Kolean, attorney-in-fact for Stefan Loren	08/05/2015
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Option vests in equal quarterly increments over a period of three years from the date of grant. Option expires on the tenth anniversary of the date of grant.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

CONFIRMING STATEMENT

This Statement confirms that the undersigned has authorized and designated Paul Bork, Daniel Clevenger, Chad Kolean and Christina Blakley, each acting singly, to execute and file on the undersigned's behalf a Form ID and all Forms 3, 4, and 5 (including any amendments thereto) that the undersigned may be required to file with the U.S. Securities and Exchange Commission as a result of the undersigned's ownership of or transactions in securities of Cellectar Biosciences, Inc. The authority of Paul Bork, Daniel Clevenger, Chad Kolean and Christina Blakley under this Statement shall continue until the undersigned is no longer required to file Forms 3, 4, and 5 with regard to the undersigned's ownership of or transactions in securities of Cellectar Biosciences, Inc. unless earlier revoked in writing. The undersigned acknowledges that Paul Bork, Daniel Clevenger, Chad Kolean and Christina Blakley are not assuming any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Statement revokes the authority of any person named in any prior confirming statement relating to the undersigned's filing obligations with respect to securities of Cellectar Biosciences, Inc. who is not named herein, and this Statement replaces and supersedes any such prior confirming statement.

Dated: March 23, 2015

Signed: /s/ Stefan D. Loren

Print Name: Stefan D. Loren